Scarica l'app Stockscreener
1.54
8.88%
-0.15
Dopo l'orario di chiusura:
1.55
0.01
+0.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.69
Aprire:
$1.67
Volume 24 ore:
5.96M
Relative Volume:
0.67
Capitalizzazione di mercato:
$462.13M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-1.0267
EPS:
-1.5
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
+10.79%
1M Prestazione:
+28.33%
6M Prestazione:
-8.88%
1 anno Prestazione:
-18.09%
Intervallo 1D:
$1.52
$1.70
Intervallo di 1 settimana:
$1.35
$1.71
Portata 52W:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Confronta PACB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.54 | 486.14M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
125.64 | 218.92B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.21 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.66 | 153.22B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.32 | 117.89B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
75.80 | 45.12B | 5.54B | 4.18B | 623.10M | 7.00 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
What makes Pacific Biosciences of California Inc. stock attractive to long term investorsDynamic profit opportunities - jammulinksnews.com
PacBio (PACB) Technology Powers Significant Genomic Research in Arab Populations | PACB Stock News - GuruFocus
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand - Yahoo.co
Publication spotlight: How Kinnex long-read RNA sequencing wins out over Illumina for transcript-level quantification - PacBio
What analysts say about Pacific Biosciences of California Inc. stockExceptional earning trajectories - Autocar Professional
Why PacBio (PACB) Stock Is Up Today - Yahoo Finance
QIAGEN’s New Sequencing Panels Boosts PacBio Expansion - StocksToTrade
Pacific Biosciences: The Shift To Razor-Blade Economics Could Be A Game Changer - Seeking Alpha
PacBio Joins 1000 Genomes Long Read Sequencing Project to Enhance Human Genomics Research - Nasdaq
Is Pacific Biosciences of California Inc. a good long term investmentPhenomenal wealth increase - Autocar Professional
QIAGEN Expands NGS Portfolio with QIAseq xHYB Long Read Panels - AInvest
What drives Pacific Biosciences of California Inc. stock priceRapid capital growth - jammulinksnews.com
Pacific Biosciences of California Inc. Stock Analysis and ForecastOutstanding capital returns - jammulinksnews.com
PacBio (PACB) Collaborates with Qiagen for Enhanced Genomic Insi - GuruFocus
QIAGEN launches long-read sequencing panels for complex genomic regions By Investing.com - Investing.com Canada
PACB Stock Rally: Bullish Signs or Temporary Spike? - StocksToTrade
PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025 - Yahoo Finance
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know - Yahoo.co
How long-read sequencing uncovers hitchhikers of the genomic galaxy in parasitic fungi - PacBio
Pacific Biosciences Stock Jumps Amid Strategic Acquisitions - StocksToTrade
Pacific Biosciences Sees Stock Uptick Following Strategic Moves - timothysykes.com
Chromosome-level genome assembly with telomeric repeats at scaffold ends for Rhabdosargus sarba - Nature
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
Further Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Could Introduce Price Risks After 29% Bounce - simplywall.st
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should Know - MSN
PACB Stock Price and Chart — NASDAQ:PACB - TradingView
Pacific Biosciences Sees Stock Surge After Latest Product Launch - timothysykes.com
Pacific Biosciences Targets Profitability by 2027 With Record Consumables Revenue - Insider Monkey
Why PACB’s Stock is Rising? - StocksToTrade
How the Long Read Sequencing Market Will Evolve by 2032Growth, - openPR.com
Barclays Adjusts Price Target for PacBio (PACB) Amid Funding Con - GuruFocus
Third Generation Sequencing Market Set to Witness Significant - openPR.com
Long Read Sequencing Market Projected to Reach USD 6.98 - GlobeNewswire
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Following a 41% decline over last year, recent gains may please Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional owners - simplywall.st
Celebrating Father’s Day with new discoveries of the Y chromosome achieved with HiFi sequencing - PacBio
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.03%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):